Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 12/2014

01.12.2014 | Original Article

Prognostic value of 18 F-FDG uptake by regional lymph nodes on pretreatment PET/CT in patients with resectable colorectal cancer

verfasst von: Byung Hyun Byun, Sun Mi Moon, Ui Sup Shin, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Sang Moo Lim

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We evaluated the ability of pretreatment 18 F-FDG uptake by regional lymph nodes to predict the survival of patients with resectable colorectal cancer.

Methods

The records of 78 patients with AJCC stage III colorectal cancer (pathologically confirmed node-positive disease without evidence of distant metastasis) treated with surgery and adjuvant chemotherapy were retrospectively reviewed. The maximum standardized uptake values of the primary tumor (SUVp) and regional lymph nodes (SUVn) were measured by pretreatment 18 F-FDG PET/CT. The ROC curve analyses and the Cox proportional hazard model were used to analyze whether SUVp, SUVn, and clinicopathologic parameters could predict disease-free survival.

Results

Although there were no significant differences between the median SUVp in the event group and that in the non-event group, the median SUVn was significantly higher in the event group (1.7) than in the non-event group (0.8, p = 0.023). Based on the ROC curve analysis, SUVn predicted the event for disease-free survival (AUC = 0.668, p = 0.02) with the optimal criterion, sensitivity, specificity, and accuracy of > 1.2, 71 %, 63 %, and 65 %, respectively. However, SUVp did not predict disease-free survival (AUC = 0.570, p = 0.349). Univariate analysis revealed that SUVn (p = 0.011) and venous invasion (p = 0.016) were associated with disease-free survival, but pathologic N stage was not (p = 0.09). By multivariate analysis, only SUVn > 1.2 independently shortened the disease-free survival (relative risk, 2.97; 95 % CI, 1.14–7.74, p = 0.026).

Conclusion

SUVn before surgery may be a useful prognostic marker in patients with AJCC stage III colorectal cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRef Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRef
2.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.CrossRef Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.CrossRef
3.
4.
Zurück zum Zitat Vather R, Sammour T, Kahokehr A, Connolly A, Hill A. Quantitative lymph node evaluation as an independent marker of long-term prognosis in stage III rectal cancer. ANZ J Surg. 2011;81:883–8.PubMedCrossRef Vather R, Sammour T, Kahokehr A, Connolly A, Hill A. Quantitative lymph node evaluation as an independent marker of long-term prognosis in stage III rectal cancer. ANZ J Surg. 2011;81:883–8.PubMedCrossRef
5.
Zurück zum Zitat Nagtegaal ID, Tot T, Jayne DG, McShane P, Nihlberg A, Marshall HC, et al. Lymph nodes, tumor deposits, and TNM: are we getting better? J Clin Oncol. 2011;29:2487–92.PubMedCrossRef Nagtegaal ID, Tot T, Jayne DG, McShane P, Nihlberg A, Marshall HC, et al. Lymph nodes, tumor deposits, and TNM: are we getting better? J Clin Oncol. 2011;29:2487–92.PubMedCrossRef
6.
Zurück zum Zitat Huh JW, Kim CH, Kim HR, Kim YJ. Factors predicting oncologic outcomes in patients with fewer than 12 lymph nodes retrieved after curative resection for colon cancer. J Surg Oncol. 2012;105:125–9.PubMedCrossRef Huh JW, Kim CH, Kim HR, Kim YJ. Factors predicting oncologic outcomes in patients with fewer than 12 lymph nodes retrieved after curative resection for colon cancer. J Surg Oncol. 2012;105:125–9.PubMedCrossRef
7.
Zurück zum Zitat Lu YY, Chen JH, Ding HJ, Chien CR, Lin WY, Kao CH. A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18 F-FDG PET or PET/CT. Nucl Med Commun. 2012;33:1127–33.PubMedCrossRef Lu YY, Chen JH, Ding HJ, Chien CR, Lin WY, Kao CH. A systematic review and meta-analysis of pretherapeutic lymph node staging of colorectal cancer by 18 F-FDG PET or PET/CT. Nucl Med Commun. 2012;33:1127–33.PubMedCrossRef
8.
Zurück zum Zitat Briggs RH, Chowdhury FU, Lodge JP, Scarsbrook AF. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol. 2011;66:1167–74.PubMedCrossRef Briggs RH, Chowdhury FU, Lodge JP, Scarsbrook AF. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol. 2011;66:1167–74.PubMedCrossRef
9.
Zurück zum Zitat Cho YB, Chun HK, Kim MJ, Choi JY, Park CM, Kim BT, et al. Accuracy of MRI and 18 F-FDG PET/CT for restaging after preoperative concurrent chemoradiotherapy for rectal cancer. World J Surg. 2009;33:2688–94.PubMedCrossRef Cho YB, Chun HK, Kim MJ, Choi JY, Park CM, Kim BT, et al. Accuracy of MRI and 18 F-FDG PET/CT for restaging after preoperative concurrent chemoradiotherapy for rectal cancer. World J Surg. 2009;33:2688–94.PubMedCrossRef
10.
Zurück zum Zitat de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18 F-FDG PET in colorectal cancer: a systematic review. J Nucl Med. 2009;50(suppl):43S–54S.PubMedCrossRef de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18 F-FDG PET in colorectal cancer: a systematic review. J Nucl Med. 2009;50(suppl):43S–54S.PubMedCrossRef
11.
Zurück zum Zitat Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18 F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.PubMedCrossRef Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18 F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.PubMedCrossRef
12.
Zurück zum Zitat Liao CT, Chang JT, Wang HM, Ng SH, Huang SF, Chen IH, et al. Preoperative [18 F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. Eur J Nucl Med Mol Imaging. 2009;36:1783–93.PubMedCrossRef Liao CT, Chang JT, Wang HM, Ng SH, Huang SF, Chen IH, et al. Preoperative [18 F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. Eur J Nucl Med Mol Imaging. 2009;36:1783–93.PubMedCrossRef
13.
Zurück zum Zitat Lee JE, Kim SW, Kim JS, Choi KY, Kang WK, Oh ST, et al. Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol. 2012;18:5072–7.PubMedCentralPubMedCrossRef Lee JE, Kim SW, Kim JS, Choi KY, Kang WK, Oh ST, et al. Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol. 2012;18:5072–7.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Krabbe CA, Pruim J, Dijkstra PU, Balink H, van der Laan BF, de Visscher JG, et al. 18 F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med. 2009;50:1940–7.PubMedCrossRef Krabbe CA, Pruim J, Dijkstra PU, Balink H, van der Laan BF, de Visscher JG, et al. 18 F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med. 2009;50:1940–7.PubMedCrossRef
15.
Zurück zum Zitat Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol. 2008;38:347–53.PubMedCrossRef Tsunoda Y, Ito M, Fujii H, Kuwano H, Saito N. Preoperative diagnosis of lymph node metastases of colorectal cancer by FDG-PET/CT. Jpn J Clin Oncol. 2008;38:347–53.PubMedCrossRef
16.
Zurück zum Zitat Na SJ, Chung YA, Maeng LS, Kim KJ, Sohn KM, Kim SH, et al. Comparison between FDG uptake and pathologic or immunohistochemical parameters in pre-operative PET/CT scan of patient with primary colorectal cancer. Nucl Med Mol Imaging. 2009;43:557–64. Na SJ, Chung YA, Maeng LS, Kim KJ, Sohn KM, Kim SH, et al. Comparison between FDG uptake and pathologic or immunohistochemical parameters in pre-operative PET/CT scan of patient with primary colorectal cancer. Nucl Med Mol Imaging. 2009;43:557–64.
17.
Zurück zum Zitat Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.PubMedCrossRef Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.PubMedCrossRef
18.
Zurück zum Zitat Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99:998–1003.PubMedCrossRef Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99:998–1003.PubMedCrossRef
19.
Zurück zum Zitat Cain KC, Lange NT. Approximate case influence for the proportional hazards regression model with censored data. Biometrics. 1984;40:493–9.PubMedCrossRef Cain KC, Lange NT. Approximate case influence for the proportional hazards regression model with censored data. Biometrics. 1984;40:493–9.PubMedCrossRef
20.
Zurück zum Zitat Aalen OO. Further results on the non-parametric linear regression model in survival analysis. Stat Med. 1993;12:1569–88.PubMedCrossRef Aalen OO. Further results on the non-parametric linear regression model in survival analysis. Stat Med. 1993;12:1569–88.PubMedCrossRef
21.
Zurück zum Zitat Lemeshow S, Hosmer Jr DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92–106.PubMed Lemeshow S, Hosmer Jr DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92–106.PubMed
22.
Zurück zum Zitat Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.PubMedCrossRef Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.PubMedCrossRef
23.
Zurück zum Zitat Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and ki-67 proliferation index. J Thorac Oncol. 2008;3:971–8.PubMedCrossRef Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and ki-67 proliferation index. J Thorac Oncol. 2008;3:971–8.PubMedCrossRef
24.
Zurück zum Zitat Kim YH, Choi JY, Do IG, Kim S, Kim BT. Factors affecting 18 F-FDG uptake by metastatic lymph nodes in gastric cancer. J Comput Assist Tomogr. 2013;37:815–9.PubMedCrossRef Kim YH, Choi JY, Do IG, Kim S, Kim BT. Factors affecting 18 F-FDG uptake by metastatic lymph nodes in gastric cancer. J Comput Assist Tomogr. 2013;37:815–9.PubMedCrossRef
25.
Zurück zum Zitat de la Fuente SG, Manson RJ, Ludwig KA, Mantyh CR. Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. J Gastrointest Surg. 2009;13:269–4.PubMedCrossRef de la Fuente SG, Manson RJ, Ludwig KA, Mantyh CR. Neoadjuvant chemoradiation for rectal cancer reduces lymph node harvest in proctectomy specimens. J Gastrointest Surg. 2009;13:269–4.PubMedCrossRef
26.
Zurück zum Zitat Sastre J, Custodio A, Sanchez JC, Ortega L, Rodriguez L, Puente J, et al. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N + rectal cancer. Anticancer Drugs. 2011;22:185–90.PubMedCrossRef Sastre J, Custodio A, Sanchez JC, Ortega L, Rodriguez L, Puente J, et al. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N + rectal cancer. Anticancer Drugs. 2011;22:185–90.PubMedCrossRef
27.
Zurück zum Zitat Martoni AA, Di Fabio F, Pinto C, Castellucci P, Pini S, Ceccarelli C, et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22:650–6.PubMedCrossRef Martoni AA, Di Fabio F, Pinto C, Castellucci P, Pini S, Ceccarelli C, et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol. 2011;22:650–6.PubMedCrossRef
28.
Zurück zum Zitat Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18 F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci. 2006;51:2198–205.PubMedCrossRef Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18 F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci. 2006;51:2198–205.PubMedCrossRef
29.
Zurück zum Zitat Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol. 2011;34:43–9.PubMedCrossRef Kornprat P, Pollheimer MJ, Lindtner RA, Schlemmer A, Rehak P, Langner C. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. Am J Clin Oncol. 2011;34:43–9.PubMedCrossRef
30.
Zurück zum Zitat Tomoda H, Taketomi A, Baba H, Kohnoe S, Seo Y, Saito T. The clinicopathological characteristics and outcome of patients with right colon cancer. Oncol Rep. 1998;5:481–3.PubMed Tomoda H, Taketomi A, Baba H, Kohnoe S, Seo Y, Saito T. The clinicopathological characteristics and outcome of patients with right colon cancer. Oncol Rep. 1998;5:481–3.PubMed
31.
Zurück zum Zitat Oh JR, Min JJ, Song HC, Chong A, Kim GE, Choi C, et al. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18 F-FDG PET/CT. Clin Nucl Med. 2012;37:e134–40.PubMedCrossRef Oh JR, Min JJ, Song HC, Chong A, Kim GE, Choi C, et al. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18 F-FDG PET/CT. Clin Nucl Med. 2012;37:e134–40.PubMedCrossRef
32.
Zurück zum Zitat Chan KK, Dassanayake B, Deen R, Wickramarachchi RE, Kumarage SK, Samita S, et al. Young patients with colorectal cancer have poor survival in the first twenty months after operation and predictable survival in the medium and long-term: analysis of survival and prognostic markers. World J Surg Oncol. 2010;8:82.PubMedCentralPubMedCrossRef Chan KK, Dassanayake B, Deen R, Wickramarachchi RE, Kumarage SK, Samita S, et al. Young patients with colorectal cancer have poor survival in the first twenty months after operation and predictable survival in the medium and long-term: analysis of survival and prognostic markers. World J Surg Oncol. 2010;8:82.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat LeBlanc JK. Imaging and management of rectal cancer. Natl Clin Pract Gastroenterol Hepatol. 2007;4:665–76.CrossRef LeBlanc JK. Imaging and management of rectal cancer. Natl Clin Pract Gastroenterol Hepatol. 2007;4:665–76.CrossRef
34.
Zurück zum Zitat Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology. 2003;227:371–7.PubMedCrossRef Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology. 2003;227:371–7.PubMedCrossRef
35.
Zurück zum Zitat Mizukami Y, Ueda S, Mizumoto A, Sasada T, Okumura R, Kohno S, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg. 2011;35:895–9.PubMedCrossRef Mizukami Y, Ueda S, Mizumoto A, Sasada T, Okumura R, Kohno S, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg. 2011;35:895–9.PubMedCrossRef
36.
Zurück zum Zitat Attenberger UI, Pilz LR, Morelli JN, Hausmann D, Doyon F, Hofheinz R, et al. Multi-parametric MRI of rectal cancer—do quantitative functional MR measurements correlate with radiologic and pathologic tumor stages? Eur J Radiol. 2014. doi:10.1016/j.ejrad.2014.03.012. Attenberger UI, Pilz LR, Morelli JN, Hausmann D, Doyon F, Hofheinz R, et al. Multi-parametric MRI of rectal cancer—do quantitative functional MR measurements correlate with radiologic and pathologic tumor stages? Eur J Radiol. 2014. doi:10.​1016/​j.​ejrad.​2014.​03.​012.
37.
Zurück zum Zitat Haldorsen IS, Grüner R, Husby JA, Magnussen IJ, Werner HM, Salvesen OO, et al. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. Eur Radiol. 2013;23:2916–25.PubMedCrossRef Haldorsen IS, Grüner R, Husby JA, Magnussen IJ, Werner HM, Salvesen OO, et al. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. Eur Radiol. 2013;23:2916–25.PubMedCrossRef
38.
Zurück zum Zitat Valles FE, Perez-Valles CL, Regalado S, Barajas RF, Rubenstein JL, Cha S. Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2013;34:35–40.PubMedCentralPubMedCrossRef Valles FE, Perez-Valles CL, Regalado S, Barajas RF, Rubenstein JL, Cha S. Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2013;34:35–40.PubMedCentralPubMedCrossRef
39.
Zurück zum Zitat Lim JS, Kim D, Baek SE, Myoung S, Choi J, Shin SJ, et al. Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2012;22:1693–700.PubMedCrossRef Lim JS, Kim D, Baek SE, Myoung S, Choi J, Shin SJ, et al. Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2012;22:1693–700.PubMedCrossRef
40.
Zurück zum Zitat Chawla S, Kim S, Loevner LA, Hwang WT, Weinstein G, Chalian A, et al. Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2011;32:778–84.PubMedCrossRef Chawla S, Kim S, Loevner LA, Hwang WT, Weinstein G, Chalian A, et al. Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2011;32:778–84.PubMedCrossRef
41.
Zurück zum Zitat Hoetjes NJ, van Velden FH, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging. 2010;37:1679–87.PubMedCentralPubMedCrossRef Hoetjes NJ, van Velden FH, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging. 2010;37:1679–87.PubMedCentralPubMedCrossRef
Metadaten
Titel
Prognostic value of 18 F-FDG uptake by regional lymph nodes on pretreatment PET/CT in patients with resectable colorectal cancer
verfasst von
Byung Hyun Byun
Sun Mi Moon
Ui Sup Shin
Ilhan Lim
Byung Il Kim
Chang Woon Choi
Sang Moo Lim
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2840-5

Weitere Artikel der Ausgabe 12/2014

European Journal of Nuclear Medicine and Molecular Imaging 12/2014 Zur Ausgabe